GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

September 30, 2006

Study Completion Date

December 31, 2006

Conditions

Prostate Cancer

Interventions

BIOLOGICAL

GTI-2040

DRUG

docetaxel

DRUG

prednisone

Trial Locations (5)

British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver

Margaret and Charles Juravinski Cancer Centre, Hamilton

London Regional Cancer Program at London Health Sciences Centre, London

Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa

Princess Margaret Hospital, Toronto

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University Health Network, Toronto

OTHER

NCT00087165 - GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter